An Open-Label, Expanded Access Program of Dupilumab in Adult Patients With Bullous Pemphigoid
Latest Information Update: 14 Jul 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Bullous pemphigoid
- Focus Expanded access; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 03 Jul 2025 Status changed from recruiting to completed.
- 03 Oct 2023 Status changed from suspended to recruiting.
- 21 Jun 2023 New trial record